spacer
home > pmps > Autumn 2010
PUBLICATIONS

Pharmaceutical Manufacturing and Packing Sourcer

pmps
Autumn 2010
   
Text
PDF
bullet
Manufacturing
Yaniv Vardi at Sparta Systems Europe Ltd argues that enterprise-wide quality management systems need to be seriously considered by manufacturers for their ability to streamline processes, centralise reporting and reduce unnecessary overheads.  
view
download pdf
bullet
Cool Chain, Cargo & Logistics
Edward A Church of the International Safe Transit Association presents the new ISTA Standard 20 while looking at the effect it will have on the shipping of temperature-controlled products, including opinions from industry insiders.  
view
download pdf
Rather than constantly purchasing and disposing of temperature-controlled packaging for thermal shipping, companies can look to recycling previously used materials that are still just as effective for the task, argues Brian Kohr at AcuTemp Thermal Systems.  
view
download pdf
Abbes Kacimi at Sofrigam weighs up the advantages and disadvantages of temperature-controlled packaging and refrigerated trucks, and offers advice on choosing between the two solutions when deciding upon a transport programme.  
view
download pdf
Training and communication are the two fundamental pillars of any cool chain partnership. Ameet Sareen at Air Canada Cargo looks at their integration in each link in the chain and gives an example of a case where both were indispensable.  
view
download pdf
Logistical considerations as a whole must be near the top of any pharma company’s to-do list. Johan Beukema at Buck Consultants International looks at outsourcing logistics to service providers and considers whether this is a viable path to take in the current climate.  
view
download pdf
bullet
Packaging, Packing & Anti-Counterfeiting
Roland Meylan at AlpVision shows how serialisation and authentication technologies must work together in order to safeguard products at all stages in the supply chain and to guarantee the safety of the patients they have been designed to protect.  
view
download pdf
Lene Blanke at Promens Medical Packaging explains that, to ensure commercial safety and viability, primary packaging should be processed thoroughly and in partnership with all parties involved, including designers, engineers and suppliers.  
view
download pdf
Gaëlle Janssens at PRO EUROPE and consultant Attilio Caligiani give an account of sustainable solutions and measures that can be employed by the packaging industry to maintain EU standards and to ensure products are environmentally friendly.  
view
download pdf
The very last stage of the packaging process creates what the consumer will finally see. Sue Benson at The Market Creative highlights some examples of how design features can improve brand awareness and contribute to compliance.  
view
download pdf
bullet
Formulations, Ingredients and Excipients
Harald Stahl at GEA Pharma Systems picks out five types of granulation process currently in use, highlighting the advantages and disadvantages of each and explaining how to select the process that will best meet your company’s production requirements.  
view
download pdf
bullet
Drug Delivery

With frequent and continuous innovations being produced in the drug delivery industry, the need for results can often obstruct the creativity that leads to true value. David Harris and Ross Jones at Sagentia consider the current situation and how it can be improved.

 
view
download pdf
Providing patients with training devices for certain delivery forms allows them to get used to the real thing, which in turn improves compliance and confidence, argues Matt Coe at One World Design & Manufacturing Group.  
view
download pdf
Frank Richter at RAUMEDIC AG explains how devices that resemble the function of familiar apparatus gives comfort to patients – especially children – which encourages compliant behaviour and can also ensure correct dosage.  
view
download pdf
bullet
MANUFACTURING
Simon Clough at Aesica Pharmaceuticals gives an assessment of how the regulatory, logistical and management challenges of manufacturing Schedule 2 controlled drugs can be overcome, while providing details of the legislation involved and the current market situation in the UK.  
view
download pdf
As their name suggests, single-use medical devices are traditionally rejected after application. However, Xiang Zhang at CERAM shows that effective sterilisation processes can often be employed by manufacturers to enable reprocessing and ultimately re-use.  
view
download pdf
bullet
the end of the line

Richard Harrop takes a sideways look at temperature-controlled packaging.

 
view
download pdf
   
spacer
Edited by
Randice Altschul
Chief Executive Officer at Pop Test and Palisades Therapeutics

Published quarterly in
February, May,
August, and November

News and Press Releases

Protagen Protein Services (PPS) reaches new level in characterizing HCP protein impurities

In response to current regulatory guidance a Mass Spectrometry (MS) based Host Cell Protein (HCP) detection approach with faster, more accurate and wider-ranging detection is essential. In order to meet the newly prevailing demands Protagen Protein Services (PPS) recently invested in more far-reaching MS capabilities: The new high-performing mass spectrometer ThermoFisher Q Exactive™ HF-X started operational service last month and brings PPS to the next level of reproducible, accurate and sensitive analyses of majorly complex samples for different aspects of translational research and biopharma applications.
More info >>

White Papers

Nasal Drug Delivery with a Focus on Chronic Rhino-Sinusitis

Aptar Pharma

Aptar Pharma have hosted a scientific roundtable on “Nasal drug delivery with a focus on chronic rhino‑sinusitis”. This international scientific forum was held in Paris, France on November 13th 2012. The roundtable was organized to explore and exchange views on the science of various forms of sinusitis and its related unmet medical needs.
More info >>

Industry Events

ASGCT 22nd Annual Meeting

29 April - 2 May 2019, Washington Hilton, Washington, D.C

The 2019 ASGCT Annual Meeting is expected to be the largest in Society history, eclipsing the mark set by the 2018 meeting just last year. Join more than 3,500 researchers, clinicians, advocates, and industry leaders in discovering the latest science and technology surrounding gene and cell therapy.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement